Mirum Pharmaceuticals, Inc.MIRMNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-6.74%
↓ 100% below average
Average (28q)
29003.05%
Historical baseline
Range
High:840850.00%
Low:-80.72%
Volatility
2899.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -6.74% |
| Q2 2025 | 0.05% |
| Q1 2025 | 4.58% |
| Q4 2024 | 38.84% |
| Q3 2024 | -2.94% |
| Q2 2024 | 1.40% |
| Q1 2024 | 4.16% |
| Q4 2023 | 18.45% |
| Q3 2023 | 18.67% |
| Q2 2023 | -6.54% |
| Q1 2023 | -24.30% |
| Q4 2022 | 18.64% |
| Q3 2022 | 3.09% |
| Q2 2022 | 5.58% |
| Q1 2022 | -13.27% |
| Q4 2021 | -8.85% |
| Q3 2021 | -13.06% |
| Q2 2021 | -8.09% |
| Q1 2021 | 28.29% |
| Q4 2020 | 85.97% |
| Q3 2020 | -13.86% |
| Q2 2020 | 7.01% |
| Q1 2020 | 20.58% |
| Q4 2019 | 18.27% |
| Q3 2019 | 4.92% |
| Q2 2019 | 138.31% |
| Q1 2019 | -80.72% |
| Q4 2018 | 840850.00% |
| Q3 2018 | 0.00% |